Logo

Garden City
Plainview
Listen to The Optimal Health Program for latest on Stem Cell Therapy Treatments
Click Here for Telemedicine Consultation & Appointment

Daily Archives for: June 22nd, 2013

Background Antifracture efficacy with supplemental vitamin D has been questioned by recent trials.

Methods We performed a meta-analysis on the efficacy of oral supplemental vitamin D in preventing nonvertebral and hip fractures among older individuals (≥65 years). We included 12 double-blind randomized controlled trials (RCTs) for nonvertebral fractures (n = 42 279) and 8 RCTs for hip fractures (n = 40 886) comparing oral vitamin D,

PURPOSE:
Higher serum levels of the main circulating form of vitamin D, 25-hydroxyvitamin D
(25(OH)D), are associated with substantially lower incidence rates of colon, breast, ovarian, renal, pancre-
atic, aggressive prostate and other cancers.
METHODS:
Epidemiological findings combined with newly discovered mechanisms suggest a new model
of cancer etiology that accounts for these actions of 25(OH)D and calcium.

Vitamin C is an essential nutrient, well known for its use in preventing scurvy and treating autoimmune illnesses and infections. Vitamin C has a long and controversial history with respect to its potential use as an anti-cancer agent. At present, vitamin C is classified as a complementary/alternative results for cancer. Recently, in vitro and animal studies discovered that high dose intravenous vitamin C acts as a pro-drug,

Context Mounting evidence indicates that vitamin B6, a coenzyme involved in nearly 100 enzymatic reactions, may reduce the risk of colorectal cancer.

Objective To conduct a systematic review with meta-analysis of prospective studies assessing the association of vitamin B6 intake or blood levels of pyridoxal 5′-phosphate (PLP; the active form of vitamin B6) with risk of colorectal cancer.

Prostate cancer is one of the common cancers seen in males. Earlier studies that have used intravenous (IV) or oral vitamin C have shown an improvement in symptoms of cancer patients and have prolonged life in terminally ill cancer patients. Today, evidence suggests that high doses of intravenous vitamin C ranging from 50 to 100 g can increase the plasma concentration of vitamin C to 14000 μmol/L.